论文部分内容阅读
目的观察临床通过氨溴索与吸入用布地奈德混悬液(普米克令舒)联合雾化治疗新生儿肺炎的疗效及安全性评价。方法 96例新生儿肺炎患儿,按照随机对照分组法分为对照组和观察组,各48例。对照组患儿均采用抗感染、纠正酸碱失衡等相关治疗,观察组患儿均于对照组治疗基础上加用氨溴索与普米克令舒联合雾化方式进行治疗。用药1周后,观察对比两组患儿临床疗效、身体特征及住院时间。结果经治疗后,观察组患儿的总有效率为95.83%,显著优于对照组的52.08%,差异有统计学意义(P<0.05)。观察组患儿的退热、啰音消失、呼吸频率恢复正常以及住院时间均显著低于对照组,差异均有统计学意义(P<0.05)。结论氨溴索与普米克令舒联合雾化治疗对于新生儿肺炎无不良反应,治疗效果较好,安全性高,值得临床重视。
Objective To observe the clinical efficacy and safety evaluation of combination of ambroxol and inhalation of budesonide suspension (pulmicort resp.) In the treatment of neonate pneumonia. Methods 96 cases of neonatal pneumonia were divided into control group and observation group according to randomized control grouping method, 48 cases each. Control children with anti-infective, correct acid-base imbalance and other related treatment, the observation group of children were treated on the basis of the control group plus ambroxol combined with Pulmicort respirator treatment. After one week of treatment, the clinical efficacy, physical characteristics and hospital stay in two groups were compared. Results After treatment, the total effective rate in the observation group was 95.83%, which was significantly better than that in the control group (52.08%), the difference was statistically significant (P <0.05). In the observation group, the fever, the disappearance of arachnoid, the resumption of respiratory rate, and the length of hospital stay in the observation group were significantly lower than those in the control group (P <0.05). Conclusion Ambroxol combined with pulmicort respules nebulization treatment for neonatal pneumonia without adverse reactions, the treatment effect is good, safe, it is worth clinical attention.